Toggle light / dark theme

Can you pass me the whatchamacallit? It’s right over there next to the thingamajig.

Many of us will experience “lethologica”, or difficulty finding words, in everyday life. And it usually becomes more prominent with age.

Frequent difficulty finding the right word can signal changes in the brain consistent with the early (“preclinical”) stages of Alzheimer’s disease – before more obvious symptoms emerge.

The Maximum Absorbency Garment (MAG)—that collects urine and feces during extravehicular activities (EVAs) that last up to 8 h. Such exposure to waste for prolonged periods of time contributes to hygiene-related medical events, including urinary tract infections and gastrointestinal distress. Historically, prior to using the MAG, astronauts have limited their food intake or eaten a low-residue diet before embarking on physically demanding spacewalks, reducing their work performance index (WPI) and posing a health risk. Furthermore, the current 0.95 L In-suit Drink Bag (IDB) does not provide sufficient water for more frequent, longer-range spacewalks, which carry greater potential for contingency scenarios requiring extended time away from a vehicle.

Increased frailty, higher incidence of diseases, and death. As the population grows older, there is a need to reveal mechanisms associated with aging that could spearhead treatments to postpone the onset of age-associated decline, extend both healthspan and lifespan. One possibility is targeting the sirtuin SIRT1, the founding member of the sirtuin family, a highly conserved family of histone deacetylases that have been linked to metabolism, stress response, protein synthesis, genomic instability, neurodegeneration, DNA damage repair, and inflammation. Importantly, sirtuins have also been implicated to promote health and lifespan extension, while their dysregulation has been linked to cancer, neurological processes, and heart disorders. SIRT1 is one of seven members of sirtuin family; each requiring nicotinamide adenine dinucleotide (NAD+) as co-substrate for their catalytic activity. Overexpression of yeast, worm, fly, and mice SIRT1 homologs extend lifespan in each animal, respectively. Moreover, lifespan extension due to calorie restriction are associated with increased sirtuin activity. These findings led to the search for a calorie restriction mimetic, which revealed the compound resveratrol; (3, 5, 4′-trihydroxy-trans-stilbene) belonging to the stilbenoids group of polyphenols. Following this finding, resveratrol and other sirtuin-activating compounds have been extensively studied for their ability to affect health and lifespan in a variety of species, including humans via clinical studies.

Aging is associated with a progressive metabolic, physiological decline and can be genetically and environmentally modified (Helfand and Rogina, 2000). The search for the molecular basis of aging led to the identification of several pathways associated with longevity including insulin/IGF-1, target of rapamycin (TOR) and the Sirtuins (Kenyon, 2010; Chen et al., 2022). The sirtuins are a family of nicotinamide adenine dinucleotide (NAD+)-dependent histone deacetylases (Haigis and Sinclair, 2010; Hall et al., 2013; Bonkowski and Sinclair, 2016; Dai et al., 2018; Singh et al., 2018). Sirtuins are also categorized as deacetylases because they catalyze the post-translational modification of signaling molecules including decrotonylation, ADP-ribosylation, diacylation, desuccinylation, demalonylation, depropynylation, delipoamidation, and deglutarylation, and other long-chain fatty acid deacylations (Feldman, Baeza, and Denu, 2013; Choudhary et al., 2014; Fiorentino et al., 2022).

In mammals, there are seven members (SIRT1-SIRT7) including SIRT1, SIRT6 and SIRT7, which are localized to the nucleus, and SIRT3, SIRT4, and SIRT5 localized to the mitochondria, SIRT2 localized to the cytosol, and SIRT1 also localized to cytosol in some cell types (Bonkowski and Sinclair, 2016). As histone deacetylases, sirtuins function by removing acetyl groups from the target proteins resulting in either inhibition or activation. SIRT1, SIRT6 and SIRT7 have many functions including: regulators of transcription, control of cellular metabolism, DNA repair, cell survival, tissue regeneration, inflammation, circadian rhythms and neuronal signaling (Haigis and Sinclair, 2010). SIRT3-5 are important for switching to mitochondrial oxidative metabolism during CR and modulate stress tolerance (Verdin et al., 2010).

The neurons that produce a sick feeling and food aversion are distinct from those that induce a feeling of fullness.

By Mariana Lenharo & Nature magazine

Next-generation anti-obesity drugs such as Wegovy can melt away weightbut they can also cause intolerable nausea. Now scientists have pinpointed a brain pathway that is involved in this common side effect, raising the prospect of effective weight-loss drugs that don’t make people sick1.

The genetically modified lymphocytes were then multiplied into the hundreds of millions in the laboratory and infused back into the patients, where they expressed the tumor-specific T-cell receptors and continued to multiply.

“By taking the natural T-cell receptors that are present in a very small number of cells and putting them into normal lymphocytes for which we have enormous numbers—a million in every thimbleful of blood—we can generate as many cancer-fighting cells as we want,” Dr. Rosenberg explained.

As part of a larger phase 2 trial, seven patients with metastatic colon cancer were treated with the experimental personalized cellular immunotherapy. All seven received several doses of the immunotherapy drug pembrolizumab (Keytruda) before the cell therapy and another immunotherapy drug called IL-2 afterward. Three patients had substantial shrinkage of metastatic tumors in the liver, lung, and lymph nodes that lasted for four to seven months. The median time to disease progression was 4.6 months.

Personal radiation protection solutions for earth and space — dr. oren milstein, phd — CEO and co-founder, stemrad.


Dr. Oren Milstein, Ph.D. is CEO and Board Member of StemRad (https://stemrad.com/), a world leader in the provision of personal radiation protection solutions and is the first company to offer life-saving protection from penetrating ionizing radiation and is making the lives of first responders, military personnel, utility personnel, medical teams, and astronauts safer without compromising mission objectives. Comprised of radiation biology experts, nuclear physicists, designers, and engineers and backed by dozens of prominent doctors and scientists including three Nobel Laureates, StemRad provides cutting-edge technology to protect these heroes on Earth and beyond.

Dr. Milstein co-founded StemRad in 2011, shortly after the Fukushima Daiichi nuclear disaster in Japan. He has been leading R\&D efforts ever since and was appointed CEO in February of 2016.

Dr. Milstein has more than 12 years of Life Sciences research experience; formerly, Dr. Milstein was an European Molecular Biology Organization (EMBO) fellow at NYU’s Skirball Institute of Biomolecular Medicine, where his research provided basic insights into the mechanism of T cell activation. Later in his career, as an NIH fellow at the Scripps Research Institute, he discovered a novel mechanism for iron deficiency anemia. Subsequently, Dr. Milstein focused his research on radiation-induced autoimmune hemolytic anemia.

Dr. Milstein received his Ph.D. degree from The Weizmann Institute of Science in 2008, where he developed novel strategies for successful bone marrow transplantation into irradiated subjects. He received his B.Sc., Magna Cum Laude, from The Hebrew University in Jerusalem. His research has resulted in several peer-reviewed publications and patents.